These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 37029499)

  • 1. The case for the therapeutic use of mechanistic/mammalian target of rapamycin (mTOR) inhibitors in xenotransplantation.
    Maenaka A; Kinoshita K; Hara H; Cooper DKC
    Xenotransplantation; 2023; 30(3):e12802. PubMed ID: 37029499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice.
    Makki K; Taront S; Molendi-Coste O; Bouchaert E; Neve B; Eury E; Lobbens S; Labalette M; Duez H; Staels B; Dombrowicz D; Froguel P; Wolowczuk I
    PLoS One; 2014; 9(4):e92684. PubMed ID: 24710396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of mTOR inhibitors in adult solid organ transplantation.
    Ventura-Aguiar P; Campistol JM; Diekmann F
    Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity.
    Ghazal K; Stenard F; Dahlqvist G; Barjon C; Aoudjehane L; Scatton O; Conti F
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):237-244. PubMed ID: 29175009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic Target of Rapamycin (mTOR) Inhibitors.
    Wang D; Eisen HJ
    Handb Exp Pharmacol; 2022; 272():53-72. PubMed ID: 35091825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Pathways Leading to Induction of Cell Death and Anti-Proliferative Properties by Tacrolimus and mTOR Inhibitors in Liver Cancer Cells.
    Navarro-Villarán E; de la Cruz-Ojeda P; Contreras L; González R; Negrete M; Rodríguez-Hernández MA; Marín-Gómez LM; Álamo-Martínez JM; Calvo A; Gómez-Bravo MA; de la Cruz J; Padillo J; Muntané J
    Cell Physiol Biochem; 2020 May; 54(3):457-473. PubMed ID: 32369692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection.
    Rosborough BR; Raïch-Regué D; Liu Q; Venkataramanan R; Turnquist HR; Thomson AW
    Am J Transplant; 2014 Sep; 14(9):2173-80. PubMed ID: 25307040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice.
    Hurez V; Dao V; Liu A; Pandeswara S; Gelfond J; Sun L; Bergman M; Orihuela CJ; Galvan V; Padrón Á; Drerup J; Liu Y; Hasty P; Sharp ZD; Curiel TJ
    Aging Cell; 2015 Dec; 14(6):945-56. PubMed ID: 26315673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
    Fine NM; Kushwaha SS
    Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RapaLink-1 outperforms rapamycin in alleviating allogeneic graft rejection by inhibiting the mTORC1-4E-BP1 pathway in mice.
    Wang N; Zhou K; Liang Z; Sun R; Tang H; Yang Z; Zhao W; Peng Y; Song P; Zheng S; Xie H
    Int Immunopharmacol; 2023 Dec; 125(Pt B):111172. PubMed ID: 37951193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation.
    Nguyen LS; Vautier M; Allenbach Y; Zahr N; Benveniste O; Funck-Brentano C; Salem JE
    Drug Saf; 2019 Jul; 42(7):813-825. PubMed ID: 30868436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin passes the torch: a new generation of mTOR inhibitors.
    Benjamin D; Colombi M; Moroni C; Hall MN
    Nat Rev Drug Discov; 2011 Oct; 10(11):868-80. PubMed ID: 22037041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of transplantation tolerance induction by autologous regulatory T cells in the pig-to-non-human primate islet xenotransplantation model.
    Shin JS; Min BH; Kim JM; Kim JS; Yoon IH; Kim HJ; Kim YH; Jang JY; Kang HJ; Lim DG; Ha J; Kim SJ; Park CG
    Xenotransplantation; 2016 Jul; 23(4):300-9. PubMed ID: 27387829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis.
    Huber S; Bruns CJ; Schmid G; Hermann PC; Conrad C; Niess H; Huss R; Graeb C; Jauch KW; Heeschen C; Guba M
    Kidney Int; 2007 Apr; 71(8):771-7. PubMed ID: 17299523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR Inhibition and Clinical Transplantation: Pancreas and Islet.
    Berney T; Andres A; Toso C; Majno P; Squifflet JP
    Transplantation; 2018 Feb; 102(2S Suppl 1):S30-S31. PubMed ID: 28230643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR Signaling Regulates Protective Activity of Transferred CD4+Foxp3+ T Cells in Repair of Acute Kidney Injury.
    Chen G; Dong Z; Liu H; Liu Y; Duan S; Liu Y; Liu F; Chen H
    J Immunol; 2016 Nov; 197(10):3917-3926. PubMed ID: 27798166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
    Schnitzbauer AA; Zuelke C; Graeb C; Rochon J; Bilbao I; Burra P; de Jong KP; Duvoux C; Kneteman NM; Adam R; Bechstein WO; Becker T; Beckebaum S; Chazouillères O; Cillo U; Colledan M; Fändrich F; Gugenheim J; Hauss JP; Heise M; Hidalgo E; Jamieson N; Königsrainer A; Lamby PE; Lerut JP; Mäkisalo H; Margreiter R; Mazzaferro V; Mutzbauer I; Otto G; Pageaux GP; Pinna AD; Pirenne J; Rizell M; Rossi G; Rostaing L; Roy A; Turrion VS; Schmidt J; Troisi RI; van Hoek B; Valente U; Wolf P; Wolters H; Mirza DF; Scholz T; Steininger R; Soderdahl G; Strasser SI; Jauch KW; Neuhaus P; Schlitt HJ; Geissler EK
    BMC Cancer; 2010 May; 10():190. PubMed ID: 20459775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells.
    Zeiser R; Leveson-Gower DB; Zambricki EA; Kambham N; Beilhack A; Loh J; Hou JZ; Negrin RS
    Blood; 2008 Jan; 111(1):453-62. PubMed ID: 17967941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapamycin Prolongs Cardiac Allograft Survival in a Mouse Model by Inducing Myeloid-Derived Suppressor Cells.
    Nakamura T; Nakao T; Yoshimura N; Ashihara E
    Am J Transplant; 2015 Sep; 15(9):2364-77. PubMed ID: 25943210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of sirolimus in solid organ transplantation.
    Augustine JJ; Bodziak KA; Hricik DE
    Drugs; 2007; 67(3):369-91. PubMed ID: 17335296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.